Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies collecting tissue samples from patients with HIV-related malignancies.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 5 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 16, 2023 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- AIDS Malignancy Consortium
- Interventions being studied
- Genetic: DNA analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: biologic sample preservation procedure; Other: flow cytometry; Other: medical chart review
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- DISEASE CHARACTERISTICS:
- Participants must have a diagnosis of a malignancy or clinical findings suggestive of a possible HIV-associated malignancy of one of three types:
- Diffuse large B-cell lymphoma
- Non-small cell lung malignancy
- The presence of any of the following conditions will exclude a participant from study enrollment:
- Absence of sufficient diagnostic tumor-biopsy tissue material to meet the protocol requirements for baseline specimen submission (minimum specimen size of 10 x 10 x 2 mm); repeat tumor biopsy will not be performed solely to meet the protocol specimen-collection requirements
- Participants whose biopsies, for the purpose of this protocol, show a diagnosis of anal intraepithelial neoplasia or cervical intraepithelial neoplasia
- Prior treatment for the study malignancy (including neo-adjuvants), since treatment can affect the mutational spectra of tumors
- HIV infection based on serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other Food and Drug Administration (FDA)-approved (licensed) HIV test; alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests PATIENT CHARACTERISTICS:
- Participants must be willing and able to sign an IRB-approved informed consent document PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Moores UCSD Cancer CenterLa Jolla, California
- UCLA Clinical AIDS Research and Education (CARE) CenterLos Angeles, California
- George Washington UniversityWashington D.C., District of Columbia
- University of MiamiMiami, Florida
- John H. Stroger Hospital of Cook CountyChicago, Illinois
- Louisiana State University Public HospitalNew Orleans, Louisiana
- Washington University School of MedicineSt Louis, Missouri
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Albert Einstein Cancer Center at Albert Einstein College of MedicineThe Bronx, New York
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, North Carolina
- University of Pennsylvania - Abramson Cancer Center at Pennsylvania HospitalPhiladelphia, Pennsylvania
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 16, 2023. Always confirm current availability with the study team.